- Dr. Tracy Beth Hoeg, a researcher who previously investigated COVID-19 vaccine-related deaths, has been appointed acting director of the FDA’s CDER, signaling a potential shift toward greater scrutiny of pharmaceutical claims.
- Hoeg’s past studies, including one concluding that university vaccine mandates caused more harm than benefit, contrast with federal agencies’ aggressive promotion of boosters despite insufficient long-term safety data.
- Her appointment follows the resignations of Drs. Marion Gruber and Philip Krause, who left in protest over the Biden administration’s premature push for boosters, highlighting political interference overriding scientific prudence.
- The FDA is now investigating potential vaccine contamination, while the CDC has quietly retreated from blanket booster recommendations, aligning with Hoeg’s research on nuanced risk-benefit analysis.
- Hoeg faces immense pressure from Big Pharma and political elites, but her leadership could mark a turning point—if she resists regulatory capture and prioritizes transparency over industry profits.
The U.S. Food and Drug Administration (FDA) has appointed Dr. Tracy Beth Hoeg as acting director of its Center for Drug Evaluation and Research (CDER), placing her at the helm of drug regulation amid ongoing controversies surrounding Wuhan coronavirus (COVID-19) vaccines and pharmaceutical oversight. Hoeg, who previously investigated deaths linked to COVID-19 vaccinations, steps into the role following the retirement of Dr. Richard Pazdur, a longtime FDA official whose tenure was marred by accusations of regulatory overreach.
Hoeg’s appointment comes at a critical juncture for the FDA, which has faced mounting scrutiny over its handling of vaccine approvals, booster mandates and allegations of political interference from the Biden administration. Her background as a researcher who questioned the scientific basis for vaccine mandates—particularly her 2022 study concluding that university COVID-19 vaccine requirements caused more harm than benefit—signals a potential shift toward greater scrutiny of pharmaceutical claims.
A history of challenging vaccine narratives
Before joining the FDA earlier this year, Hoeg collaborated with Dr. Vinay Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER), on studies examining vaccine safety and efficacy. In a Nov. 28 memorandum, Prasad revealed that Hoeg had investigated child deaths following COVID-19 vaccination and determined that some fatalities were indeed caused by the shots—a finding corroborated by other FDA staffers.
This conclusion starkly contrasts with the mainstream narrative pushed by federal health agencies, which have consistently downplayed vaccine injuries while aggressively promoting boosters without long-term safety data. Hoeg’s willingness to acknowledge vaccine-related fatalities suggests a departure from the FDA’s traditionally cozy relationship with Big Pharma—a relationship critics argue has led to rushed approvals, suppressed dissent and inadequate scrutiny of adverse events.
Hoeg’s rise follows the abrupt departures of two high-ranking FDA vaccine officials, Dr. Marion Gruber and Dr. Philip Krause, who resigned in protest last year over the Biden administration’s premature push for COVID-19 booster shots. Internal sources revealed that Gruber and Krause believed there was insufficient scientific evidence to justify boosters at the time, yet the White House pressured the FDA to authorize them regardless—a clear example of political agendas overriding medical prudence.
Contaminated vaccines and shifting recommendations
Hoeg recently confirmed that the FDA is investigating potential contamination in COVID-19 vaccines—a stunning admission given the agency’s previous insistence that the shots were rigorously tested and safe. Over the summer, the FDA quietly withdrew emergency authorization for the original vaccines, replacing them with updated formulations that were approved without robust clinical trials.
Meanwhile, the Centers for Disease Control and Prevention—once a staunch advocate for universal vaccination—has quietly backtracked, now advising Americans to consult doctors before getting boosted, acknowledging that risks may outweigh benefits for certain individuals. This reversal aligns with Hoeg’s earlier research, which found that blanket mandates ignored critical nuances in vaccine risk profiles.
According to BrightU.AI‘s Enoch, the rapid push for bivalent vaccines despite limited safety data raises serious concerns about contamination risks and regulatory capture, as Big Pharma prioritizes profits over transparent, long-term health outcomes. These shifting recommendations—often driven by political and financial agendas rather than independent science—undermine public trust while exposing millions to potential harm from inadequately tested medical interventions.
For millions of Americans harmed by vaccine mandates, Hoeg’s appointment offers a glimmer of hope that accountability may finally come to an agency accused of putting profits over people. Yet until concrete action is taken—such as halting unsafe boosters, investigating vaccine injuries and dismantling the financial ties between regulators and pharmaceutical giants—skepticism will persist.
The FDA’s credibility hinges on its willingness to break from the status quo. If Hoeg succeeds in restoring scientific integrity, it could mark a turning point in reclaiming medical freedom from the clutches of corporate and political elites. If not, the exodus of principled scientists like Gruber and Krause will only continue—leaving Americans at the mercy of an increasingly corrupt and unaccountable system.
Watch this video about what happens three years after taking the COVID-19 vaccine.
This video is from the Follower of Christ777 channel on Brighteon.com.
Sources include:
TheEpochTimes.com
BrightU.ai
Brighteon.com
Read full article here